Therefore, while PDE10A inhibition shows promise as a therapeutic strategy under controlled pharmacologic conditions, these divergent outcomes emphasize the need for tumor-specific molecular profiling and careful consideration of potential pro-tumorigenic consequences when translating PDE10A-targeted therapies to the clinic (Figure 2). This evidence concerns the gene PDE10A and neoplasm.